Press Releases


Warning: Creating default object from empty value in /var/www/vhosts/mimetogen.com/mimetogen.com/plugins/system/gantry/overrides/3.3/2.5/com_content/category/default_articles.php on line 17
Mimetogen pharmaceuticals completes enrollment of mim-728 phase 3 trial for tavilermide for dry eye disease 31 March 2020